Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. [PDF]
NPJ Genom Med, 2016 Metastatic basal cell carcinomas are rare malignancies harbouring Hedgehog pathway alterations targetable by SMO antagonists (vismodegib/sonidegib). We describe, for the first time, the molecular genetics and response of a patient with Hedgehog inhibitor-
Ikeda S +8 more
europepmc +2 more sources
c-FOS Expression in Metastatic Basal Cell Carcinoma with Spontaneous Basosquamous Transition [PDF]
Acta Dermato-Venereologica, 2023 is missing (Short communication)
Yu Kurokami +4 more
doaj +2 more sources
Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. [PDF]
J Eur Acad Dermatol Venereol, 2018 Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult‐to‐treat populations, have had limited treatment options.
Lear JT +19 more
europepmc +2 more sources
Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test [PDF]
Dermatologic Therapy, 2019 IntroductionNon-melanoma skin cancer (NMSC) is the most common type of human tumor, with an estimated five million new cases each year. NMSC has been described as having a major impact on the health-related quality of life of the patient. Vismodegib is a
Alessia Villani +4 more
openalex +2 more sources
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. [PDF]
JAMA Dermatol, 2016 IMPORTANCE Tumor resistance is an emerging problem for Smoothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC). Arsenic trioxide and itraconazole antagonize the hedgehog (HH) pathway at sites distinct from those treated by SMO inhibitors.
Ally MS +11 more
europepmc +2 more sources
A Case of Metastatic Basal Cell Carcinoma Treated with Cisplatin and Adriamycin
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2017 A 72-year-old man was referred to our hospital for treatment of an ulcer that had been growing on his back for 10 years. Physical examination showed an ulcerated tumor from the neck to the back and swollen cervical lymph nodes. The tumor size was 12×9 cm.
Akiko Kanzaki +6 more
openalex +3 more sources
Metastatic basal cell carcinoma: Case series and literature review [PDF]
Brazilian Journal of OtorhinolaryngologyObjective: To present a metastatic head and neck basal cell carcinoma (BCC) series treated by a university teaching service between 1993 and 2021. Methods: A review of medical records of 500 patients with high-risk BCC in the head and neck was performed.
Mariana Gonçalves Rodrigues +6 more
doaj +2 more sources
Metastatic Basal Cell Carcinoma
, 2012 Basal cell carcinoma (BCC) is the most common skin malignancy, accounting for up to 80% of all cancers arising from the epidermis.1 The disease usually presents as a slow growing, non-healing raised lesion with rolled borders and telangiectasias. These cancers arise from cells lining the deepest layer of the epidermis.
Anthony Vu, Donald Jr.
openalex +4 more sources
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma [PDF]
npj Precision OncologyWe report the basal cell cancer (BCC) cohort of the SWOG/NCI 1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART), a phase II prospective, multicenter basket trial of nivolumab and ipilimumab. The primary endpoint was objective response rate (
Sandip P. Patel +17 more
doaj +2 more sources
Metastatic Basal Cell Carcinoma of the Eyelid
Delhi Journal of Ophthalmology, 2014 Metastatic basal cell carcinoma (MBCC) arising from the eyelid is a very rare entity. We describe a case of a 65 year old female who presented to us with a mass lesion on the left upper eyelid.
Bhavna Chawla +3 more
doaj +4 more sources